Weight loss drug linked with reduced need for diuretics in heart failure patients

STEP-HFpEF analysis presented in a late breaking science session today at Heart Failure 2024

2024-05-13

(Press-News.org) Lisbon, Portugal – 13 May 2024: Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction (HFpEF) regardless of diuretic use, according to late breaking research presented today at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC).1

HFpEF is a condition in which the heart pumps normally but is too stiff to fill properly, rendering the heart unable to support the body’s need for oxygen-rich blood. The condition is becoming more common as populations age and levels of obesity and sedentary lifestyles rise.2 Symptoms of HFpEF can include shortness of breath – often with exertion – fatigue, and swollen ankles.

The STEP-HFpEF and STEP-HFpEF DM trials evaluated once-weekly semaglutide treatment vs. placebo in patients with obesity-related HFpEF, without and with diabetes, respectively.3,4 Both studies showed a significant improvement with semaglutide for heart failure symptoms, physical limitations, weight loss, and six-minute walk distance compared to placebo. This pre-specified analysis of pooled data from the two trials investigated whether the effects of semaglutide vs. placebo varied according to baseline diuretic use. In addition, the effects of semaglutide vs. placebo on changes in diuretic therapy use and dose during the trials was evaluated.

In both trials, patients had obesity-related HFpEF with left ventricular ejection fraction ≥45%, body mass index ≥30 kg/m2, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) <90, evidence of elevated left ventricular filling pressures, structural heart abnormalities plus elevated natriuretic peptides, or recent heart failure hospitalisation plus structural abnormalities or ongoing need for diuretic therapy. Patients were randomised 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks. The dual primary endpoints were change in KCCQ-CSS (a standard measure of heart failure-related symptoms and physical limitations) and percentage change in body weight from baseline to 52 weeks. Patients were stratified by baseline diuretic use (none, non-loop diuretic only, loop diuretic).

A total of 1,145 patients were included (529 in STEP-HFpEF and 616 in STEP-HFpEF DM) from 129 sites across 18 countries in Asia, Europe, North America, and South America. The average age was ~70 years and ~50% were women. At baseline, 220 patients were not receiving diuretics, 223 were receiving non-loop diuretics only, and 702 were receiving loop diuretics.

Regarding the first primary endpoint of change in heart failure-related symptoms and physical limitations from baseline to 52 weeks, semaglutide improved KCCQ-CSS in all diuretic subgroups, but the magnitude of improvement was greater in patients receiving loop diuretics compared to those not on loop diuretics, with an adjusted mean difference vs. placebo of +9.3 (95% confidence interval [CI] +6.5, +12.1) vs. +4.7 points (+1.3, +8.2), respectively; p interaction=0.042.

For the second primary endpoint of percentage change in body weight from baseline to 52 weeks, semaglutide had a consistent beneficial effect across diuretic use categories. The adjusted mean difference vs. placebo ranged from -8.8% (95% CI -10.3, -6.3) to -6.9% (95% CI -9.1, -4.7) from no diuretics to the highest loop diuretic dose category; p interaction=0.39. Semaglutide had consistent beneficial effects on all secondary efficacy endpoints (including six-minute walk distance) across diuretic subgroups (p interaction=0.24-0.92).

Between baseline and 52 weeks, loop diuretic dose decreased by 17% in the semaglutide group vs. a 2.4% increase in the placebo group (p<0.0001). Semaglutide (vs. placebo) was more likely to result in loop diuretic dose reduction (odds ratio [OR] 2.67, 95% CI 1.70, 4.18) and less likely to result in loop diuretic dose increase (OR 0.35, 95% CI 0.23, 0.53); p<0.001 for both. There were fewer serious adverse events with semaglutide vs. placebo across diuretic subgroups.

Study author Dr. Kavita Sharma of Johns Hopkins University School of Medicine, Baltimore, US, said: “Semaglutide improved symptoms, physical limitations and led to greater weight loss across diuretic use categories in patients with HFpEF. In addition, there was evidence of a significant reduction in average loop diuretic dose, a lower likelihood of diuretic treatment escalation, and a greater likelihood of diuretic treatment de-escalation with semaglutide versus placebo – parameters that indicate disease-modifying effects of semaglutide, and are associated with better long-term clinical outcomes in this patient population.”

Authors: ESC Press Office
Tel: +33 (0)489 872 075

Email: press@escardio.org

Follow us on X @ESCardioNews

Notes to editor

Funding: The STEP-HFpEF Programme was funded by Novo Nordisk.

Disclosures: Dr. Kavita Sharma receives grant funding from the American Heart Association, Amgen, and Foundation for the National Institutes of Health (FNIH), and receives honoraria as an advisory board member and/or consultant for Amgen, Alleviant, AstraZeneca, Bayer, Boehringer-Engelheim, Edwards LifeSciences, NovoNordisk, and Novartis.

References and notes

1The STEP-HFpEF analysis will be presented during the session ‘Late Breaking Clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy’ which takes place on 13 May 2024 at 13:57 WEST in Room 1.

2Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC Scientific Statement. J Am Coll Cardiol. 2023;81(18):1810–1834.

3Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–1084.

4Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394–1407.

About Heart Failure 2024 & World Congress on Acute Heart Failure
Heart Failure is the annual congress of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). #HeartFailure2024

About the Heart Failure Association

The Heart Failure Association (HFA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

Information for journalists about registration for Heart Failure 2024

Heart Failure 2024 takes place 11 to 14 May at the Lisbon Congress Centre, Portugal and online. Explore the scientific programme.

Free registration applies to accredited press. Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy. The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid. The ESC Press Office decision is final regarding all press registration requests. END

ELSE PRESS RELEASES FROM THIS DATE:

Getting out of the political echo chamber

2024-05-13

Civilized political debates may seem increasingly out of reach as democracies across the world face rising polarization, but people still want to discuss issues with people they disagree with – especially those who present themselves as balanced and willing to seek solutions that work for everyone or open to learning new information, according to two studies published by the American Psychological Association. One study, published in the Journal of Experimental Psychology: General, examined how U.S. politicians and ordinary Americans with opposing political beliefs could share their ideas on divisive issues in a way that improved respect regardless of political ...

Alarming rise of electronic vaping use in U.S. adolescents

2024-05-13

Electronic vapor products (EVPs), also known as e-cigarettes or vaping devices, have an allure because of their marketed image as a safer alternative to traditional cigarette smoking and for their variety of appealing flavors. Yet, they contain many substances beyond nicotine, including propylene glycol, glycerin, flavorings and potentially harmful chemicals such as formaldehyde and metals, which could pose significant health risks such as respiratory disease, cardiovascular disease and cancer. Vaping also is strongly linked with a serious medical condition that damages the lungs due to the vitamin E acetate, an additive used ...

More than half of Americans give to charity at checkout, survey shows

2024-05-13

BINGHAMTON, N.Y. -- 53% of Americans give impulsively to charities at the checkout, and certain demographics tend to give more, according to a new survey conducted by faculty at Binghamton University, State University of New York. From supermarkets to retail, Americans are used to being asked for donations while making in-person or online purchases – whether by rounding up, donating a set amount or purchasing a token. Industry reports reveal how money is being raised – checkout charity campaigns brought in almost $750 million in 2022, with campaigns through ...

Taking electroretinography to the next level with a soft multi-electrode system

2024-05-13

Eye diseases are becoming more prevalent worldwide, partly because of the aging population, but also because of our greatly increased screen time compared to previous generations. Considering our use of displays will most likely keep rising due to technologies such as virtual and augmented reality, we must improve our diagnostic techniques for the early detection and monitoring of ocular diseases. Among the arsenal of tools ophthalmologist have at their disposal, electroretinography (ERG) still holds much-untapped potential. Simply put, ERG consists of taking measurements of the electrical ...

New Study: The price tag of phasing-out coal

2024-05-13

Coal phase-out is necessary to solve climate change, but can have negative impacts on workers and local communities dependent on coal for their livelihoods. Researchers at Chalmers University of Technology in Sweden and Central European University in Austria have studied government plans for coal phase-out around the world and discovered that more than half of such plans include monetary compensation to affected parties. This planned compensation globally amounts to USD 200 billion, but it excludes ...

Dramatic increase in fentanyl seized by authorities in last six years

2024-05-13

The number of illicit fentanyl seizures by law enforcement in the United States grew by more than 1,700 percent between 2017 and 2023, according to a new analysis. Further, the share of total fentanyl seizures that involved pills quadrupled over the same period–with the 115.6 million pills seized in 2023 representing 49 percent of total seizures. This is the first time that such up-to-date seizure data has been published differentiating between fentanyl powder and pills, says the research team led by experts at NYU Grossman School of Medicine and the University of Florida. Law enforcement drug seizures are used as a proxy for drug availability ...

What makes a memory? It may be related to how hard your brain had to work

2024-05-13

New Haven, Conn. — The human brain filters through a flood of experiences to create specific memories. Why do some of the experiences in this deluge of sensory information become “memorable,” while most are discarded by the brain? A computational model and behavioral study developed by Yale scientists suggests a new clue to this age-old question, they report in the journal Nature Human Behavior. “The mind prioritizes remembering things that it is not able to explain very well,” said Ilker Yildirim, an ...

Over 115 million pills containing illicit fentanyl seized by law enforcement in 2023

2024-05-13

Law enforcement seizures of illicit fentanyl increased dramatically in number and size between 2017 to 2023 in the U.S., especially in pill form, according to a new study funded by the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA). The number of individual pills containing fentanyl seized by law enforcement was 2,300 times greater in 2023 compared to 2017, with 115,562,603 pills seized in 2023 vs. 49,657 in 2017. The proportion of fentanyl pill seizures to the total number of fentanyl seizures more than quadrupled, ...

Nature's 3D printer: bristle worms form bristles piece by piece

2024-05-13

A new interdisciplinary study led by molecular biologist Florian Raible from the Max Perutz Labs at the University of Vienna provides exciting insights into the bristles of the marine annelid worm Platynereis dumerilii. Specialized cells, so-called chaetoblasts, control the formation of the bristles. Their mode of operation is astonishingly similar to that of a technical 3D printer. The project is a collaboration with researchers from the University of Helsinki, Vienna University of Technology and Masaryk University in Brno. The study was recently published in the renowned journal Nature Communications. Chitin is ...

Research shows that ‘softer’ proteins can cross into the nucleus quicker

2024-05-13

Researchers at the Francis Crick Institute and King’s College London have discovered that how soft or rigid proteins are in certain regions can dictate how fast or slow they enter the nucleus. Proteins need to come in and out of the nucleus, the control centre of the cell, to give different functions, such as telling the nucleus to switch on or off certain genes. These proteins cross using a channel on the edge of the nucleus called the ‘nuclear pore complex’. Previous research has shown that the size and composition of these proteins change how easily they can cross, but now this research, published today in Nature Physics, has shown that mechanical properties can also ...

Weight loss drug linked with reduced need for diuretics in heart failure patients

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: